Plus Therapeutics Regains Compliance With Two Nasdaq Listing Rules

MT Newswires Live08-26

Plus Therapeutics (PSTV) said Tuesday the Nasdaq confirmed that it has regained compliance with two of the stock exchange's listing rules.

Plus is now in compliance with the Market Value of Listing Securities standard, which requires certain companies to maintain a market value of listed securities of at least $35 million, and the alternative stockholders' equity threshold, which requires certain companies to maintain stockholders' equity of at least $2.5 million, the company said, citing a letter from Nasdaq.

Nasdaq has extended the deadline for the company to regain compliance with the $1.00 bid price rule to Nov. 12 from Sept. 8, due to its compliance with two criteria mentioned, Plus said.

Plus remains under Nasdaq's one-year panel monitoring period through Aug. 22, 2026, the company said.

The company's shares were up more than 7% in recent premarket activity on Tuesday.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2562473519?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-26 20:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2562473519","market":"nz","top_or_hot":-1,"title":"Plus Therapeutics Regains Compliance With Two Nasdaq Listing Rules","media":"MT Newswires Live","content":"<html><body><p> Plus <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (PSTV) said Tuesday the Nasdaq confirmed that it has regained compliance with two of the stock exchange's listing rules.</p><p>Plus is now in compliance with the Market Value of Listing Securities standard, which requires certain companies to maintain a market value of listed securities of at least $35 million, and the alternative stockholders' equity threshold, which requires certain companies to maintain stockholders' equity of at least $2.5 million, the company said, citing a letter from Nasdaq.</p><p>Nasdaq has extended the deadline for the company to regain compliance with the $1.00 bid price rule to Nov. 12 from Sept. 8, due to its compliance with two criteria mentioned, Plus said.</p><p>Plus remains under Nasdaq's one-year panel monitoring period through Aug. 22, 2026, the company said.</p><p>The company's shares were up more than 7% in recent premarket activity on Tuesday.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Plus Therapeutics Regains Compliance With Two Nasdaq Listing Rules</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPlus Therapeutics Regains Compliance With Two Nasdaq Listing Rules\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-08-26 20:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Plus <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (PSTV) said Tuesday the Nasdaq confirmed that it has regained compliance with two of the stock exchange's listing rules.</p><p>Plus is now in compliance with the Market Value of Listing Securities standard, which requires certain companies to maintain a market value of listed securities of at least $35 million, and the alternative stockholders' equity threshold, which requires certain companies to maintain stockholders' equity of at least $2.5 million, the company said, citing a letter from Nasdaq.</p><p>Nasdaq has extended the deadline for the company to regain compliance with the $1.00 bid price rule to Nov. 12 from Sept. 8, due to its compliance with two criteria mentioned, Plus said.</p><p>Plus remains under Nasdaq's one-year panel monitoring period through Aug. 22, 2026, the company said.</p><p>The company's shares were up more than 7% in recent premarket activity on Tuesday.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2562473519","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2562473519","pubTimestamp":1756209816,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Plus Therapeutics  said Tuesday the Nasdaq confirmed that it has regained compliance with two of the stock exchange's listing rules.Plus is now in compliance with the Market Value of Listing Securities standard, which requires certain companies to maintain a market value of listed securities of at least $35 million, and the alternative stockholders' equity threshold, which requires certain companies to maintain stockholders' equity of at least $2.5 million, the company said, citing a letter from Nasdaq.Nasdaq has extended the deadline for the company to regain compliance with the $1.00 bid price rule to Nov. 12 from Sept. 8, due to its compliance with two criteria mentioned, Plus said.Plus remains under Nasdaq's one-year panel monitoring period through Aug. 22, 2026, the company said.The company's shares were up more than 7% in recent premarket activity on Tuesday.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","BK4112":"金融交易所和数据","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","BK4007":"制药","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","BK4539":"次新股","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","NDAQ":"纳斯达克OMX交易所","PSTV":"Plus Therapeutics, Inc.","BK4585":"ETF&股票定投概念","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","BK4139":"生物科技","LENZ":"Therapeutics",".IXIC":"NASDAQ Composite","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC"},"translate_title":"Plus Therapeutics重新遵守两项纳斯达克上市规则","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":1,".IXIC":1,"NQmain":1,"LENZ":1,"PSTV":0.9},"content_text":"Plus Therapeutics (PSTV) said Tuesday the Nasdaq confirmed that it has regained compliance with two of the stock exchange's listing rules.Plus is now in compliance with the Market Value of Listing Securities standard, which requires certain companies to maintain a market value of listed securities of at least $35 million, and the alternative stockholders' equity threshold, which requires certain companies to maintain stockholders' equity of at least $2.5 million, the company said, citing a letter from Nasdaq.Nasdaq has extended the deadline for the company to regain compliance with the $1.00 bid price rule to Nov. 12 from Sept. 8, due to its compliance with two criteria mentioned, Plus said.Plus remains under Nasdaq's one-year panel monitoring period through Aug. 22, 2026, the company said.The company's shares were up more than 7% in recent premarket activity on Tuesday.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2562473519","isCrawlerRequest":true}